Interviews were conducted with patient ambassadors, who participated in the clinical trials, to understand perspectives and experiences of patients switching from daily oral ARV therapy* to CABENUVA.1
Patient experiences with CABENUVA after receiving 1 month of oral lead-in of cabotegravir and rilpivirine. Individual patient experiences are not indicative of all patient experiences or clinical trial results.
*In ATLAS, daily oral ARV therapy consisted of 2 NRTIs plus a third agent (INSTI, NNRTI, or PI). In FLAIR, daily oral ARV therapy included abacavir/dolutegravir/lamivudine or dolutegravir plus 2 NRTIs.1,2
ARV=antiretroviral therapy; INSTI=INSTI=integrase strand transfer inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; PI=protease inhibitor.
“When I was taking daily HIV pills, I had to worry about storing the medication and where I was going to hide it... Once I started CABENUVA injections, I had privacy with not having to store HIV pills and instead focus on my treatment appointment once a month. Sure, there is some pain involved in the injections, but it's worth it to me.”
-Orlando, clinical trial participant and patient ambassador
“With CABENUVA injections, I feel a sense of independence from not having to take a pill at the same time every day and fearing that I missed it. Instead of stressing about daily treatment, I can focus on treatment once a month. Even though it's just a few seconds a day to take a pill, I now don't have to remember to take my HIV treatment until my next appointment.”
-Mark, clinical trial participant and patient ambassador
“Until I stopped taking the daily HIV pill, I didn’t appreciate how much it impacted my every day. Now, I don’t have to worry about taking treatment every day, instead, once a month. Being liberated from taking HIV medication daily makes life different in a way – you’re not a different person, but it changes your day-to-day living with the disease. I do have to plan for appointments around work, and that was a change, but now I'm used to the process.”
-Jayson, clinical trial participant and patient ambassador
- Data on File, ViiV Healthcare.
- CABENUVA [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2021.